Clinical Trial News

French researchers developed a hydrogel delivery system for semaglutide, potentially reducing dosing to once a month, easing adherence for type 2 diabetes and obesity patients. The hydrogel, tested in vitro and on rats, showed sustained release over 1-3 months with no adverse reactions, paving the way for future pig trials and potential clinical trials.

Merck and Daiichi Sankyo announced interim Phase 2 trial results for lung cancer treatment ifinatamab deruxtecan (I-DXd), showing objective response rates of ~55% and ~26% at 12 mg/kg and 8 mg/kg doses, respectively. The 12 mg/kg dose led to 23 partial responses, while the 8 mg/kg dose resulted in one complete and 11 partial responses. Median overall survival was 11.8 months and 9.4 months for the respective doses. Preliminary intracranial ORRs were 50.0% and 66.7% across the two dose groups. Adverse events led to 17% and 6.5% dropouts for the respective doses. The 12 mg/kg dose is selected for the trial's expansion part, with data to be presented at the World Conference on Lung Cancer in San Diego.

Prevent Blindness partners with IAPB for World Sight Day focusing on children's vision, hosting events and launching a tool kit with the National Association of School Nurses. The FDA grants Orphan Drug Designation to SKG1108 for retinitis pigmentosa treatment. InMed Pharmaceuticals secures patents for an ocular drug delivery formulation for AMD. A study validates the accuracy of mobile ophthalmology applications like Eye Handbook for vision assessment.

Lisocabtagene maraleucel (liso-cel) improved response outcomes in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients, with consistent results across high-risk features. Lower tumor burden and fewer prior treatments correlated with better responses. The objective response rate (ORR) and complete response (CR) rates varied by disease characteristics, but overall, liso-cel showed efficacy even in high-risk patients. Inflammatory markers, bulky disease, and lower creatine clearance rates increased the risk of neurological toxicity.

Tryptamine Therapeutics (AU:TYP) announces AGM on Nov 8, 2024, with director nominations closing Sep 27. The biotech firm reports significant progress with TRP-8803 in treating binge eating disorder and explores treatments for fibromyalgia and irritable bowel syndrome.

Recreational drug use triples risk for repeat serious cardiovascular events within one year of hospitalization, according to a study presented at the European Society of Cardiology Congress 2024. The study, involving 1,392 patients, found that 11% tested positive for recreational drugs, with 7% experiencing major adverse cardiovascular and cerebrovascular events (MACCE) at one year, significantly higher among drug users (13% vs. 6%).

Electroacupuncture added to standard antiemetic therapy significantly increased complete protection from chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving highly emetogenic chemotherapy, with a higher rate of complete protection during the delayed stage.

The phase 3 ECHELON-3 study showed that adding brentuximab vedotin to lenalidomide and rituximab significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates (ORR) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had received at least 2 prior lines of therapy. The triplet regimen resulted in a 47% reduction in the risk of disease progression or death and an ORR of 64.3% vs 41.5% with the doublet. The benefits were consistent across key subgroups, with manageable safety profiles.

Study approved by Fudan University Shanghai Cancer Center (NCT04461990). FUSCC, DUKE, and I-SPY1 cohorts analyzed for breast cancer prognosis and treatment response using DCE-MRI and multiomic data. FUSCC cohort included 466 participants with prognosis information, DUKE 619, and I-SPY1 128. Primary endpoints were relapse-free survival (RFS) and pathological complete response (pCR). Radiomic features extracted and analyzed for prognostic and treatment response prediction.

Maxim Group's Jason McCarthy maintains Buy rating on Unicycive Therapeutics (UNCY) due to the NDA submission for OLC, potential cost savings, and favorable study results. Despite price target reduction due to TDAPA uncertainties, OLC's approval could unlock significant revenue. UNCY's stock has dropped 76.86% over six months.